Pfizer Inc. (PFE)
Pfizer's Q3 Earnings Beat, Paxlovid Drives Sales Guidance Increase
PFE beats third-quarter estimates for earnings and sales. It raises 2024 earnings and revenue expectations.
Pfizer (PFE) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Pfizer (PFE) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates
Pfizer (PFE) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to loss of $0.17 per share a year ago.
Pfizer ups guidance as demand for Covid-19 products grows
Pfizer Inc (NYSE:PFE, ETR:PFE) has lifted full-year revenue guidance on the back of a rebound in demand for its Covid-19 products. Revenue is expected to sit between $61 billion and $64 billion over the year, Pfizer said in third-quarter results on Tuesday, marking a $1.5 billion increase on previous expectations.
Pfizer Lifts Revenue Outlook, McDonald's Sees U.S. Sales Growth in Q3
Pfizer Q3 earnings beat expectations, driven by Paxlovid sales. Cost-saving goals aim for $4B by 2027 as Covid demand slows.
Pfizer's earnings crush estimates as company raises guidance
Drug company Pfizer saw strong growth for its heart-disease drugs and migraine treatment.
Pfizer raises profit forecast after beating third-quarter estimates
Pfizer raised its full-year profit forecast after better-than-expected sales of its COVID-19 treatment helped it beat Wall Street estimates for third-quarter earnings on Tuesday.
Pfizer tops earnings estimates, hikes full-year guidance as Covid products help sales
Pfizer reported third-quarter revenue and adjusted profit that blew past expectations. The company hiked its full-year outlook as its Covid vaccine and antiviral pill Paxlovid helped boost sales.
Pfizer, McDonald's Q3 Earnings to Set Early Market Tone; Alphabet, AMD Follow Post-Close
Pfizer's rebound and McDonald's E. coli impact headline pre-market earnings; post-close focus shifts to Alphabet and AMD.
Will Non-COVID Drugs Again Boost Pfizer's Top Line in Q3 Earnings?
Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.
Will Pfizer Beat Earnings In Q3?
Pfizer (NYSE: PFE) is scheduled to report its Q3 2024 results on Tuesday, October 29. We expect the company to post revenue of $15.1 billion and earnings of $0.63 on a per share and adjusted basis, slightly above the consensus estimates of $14.9 billion and $0.62, respectively.
Pfizer management looks to show turnaround as Starboard looms
Pfizer's quarterly financial report on Tuesday comes at a critical moment for the U.S. drugmaker and its CEO, as activist hedge fund Starboard Value ramps up the pressure to demonstrate concrete results of a promised turnaround.
